Orexigen Therapeutics, Inc. (NASDAQ: OREX) and Valeant Canada, a subsidiary of Valeant Pharmaceuticals Intl
Inc (NYSE: VRX), struck an agreement on
commercialization and distributorship for Contrave. Following the news, Orexigen traded up by more than 12 percent in the
pre-market trading.
Orexigen said that the agreement terms made Valeant responsible for receiving regulatory approval from Canada for all
commercialization activity and expenses. The company would supply Contrave tablets for an agreed transfer price based on some
potential regulatory and sales milestone payments.
The American firm expects the Canadian firm to file for regulatory approval with Health Canada before January next year. Both
the companies disclosed a commercialization deal for Mysimba earlier in March, and they expect to launch the product in 11 nations
in the fourth quarter of the current year.
Related Link: Orexigen
Reports Commercialization, Distributorship Deal with Laboratorios Farmaceuticos Rovi in Spain
Orexigen CEO Mike Narachi said, "Valeant Canada has a growing portfolio of innovative medicines addressing cardiometabolic
disease, as well as strong regulatory and commercial capabilities, and we believe they are an ideal partner for Contrave in Canada.
Partnering with strong pharmaceutical companies outside the United States supports our global mission to improve the health and
lives of patients struggling to lose weight and allows Orexigen to realize the global value of Contrave / Mysimba."
While Orexigen traded up by 14.85 percent to $4.40, Valeant traded down by 1.62 percent, to $29.75 at time of publication
minutes after Tuesday's opening bell.
Full ratings
data available on Benzinga Pro.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win
a $20 Amazon gift card!
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.